New therapeutic possibilities for various diseases are made possible via mRNA. The adaptability of in vitro transcribed (IVT) mRNA is largely due to its simpler cell-free manufacture, cell cycle-independent performance, and risk-free insertional mutagenesis.

There are more possibilities for tailored medicines due to the simple and rapid mRNA production workflow, such as patient-specific cancer vaccinations or protein replacement for rare diseases.

Workflow is streamlined from gene synthesis to IVT mRNA generation with GenScript’s mRNA production solution. The quality and expression effectiveness of the mRNA are guaranteed by GenScript’s patented production technology, which is optimized for mRNA production.

One-stop solution for all mRNA needs

  • Gene synthesis
  • mRNA synthesis
  • Linearization
  • Plasmid preparation


Catalog mRNA

The commercially available mRNA has been enhanced with a 5’ cap and polyA tails and is prepared for use in any research project.

Plasmid DNA linearization

High-quality linearized DNA plasmid for more reliable and consistent synthesis of mRNA.

Why GenScript?

Integrated production process

Providing services for the production of mRNA and genes.

Experienced team with optimized production platform

Spend less time and effort creating and generating mRNA.

Quality control and specification

Source: GenScript

QC Item Test Method Specification RUO
Identification Appearance Visual Inspect Clear and free of foreign particles
RNA Length Capillary Electrophoresis Target ± 30%
RNA Length Agarose Gel Electrophoresis Expected size band detected
Poly A Length Enzyme digestion and CE Target ± 30%
RNA Content UV Absorbance Target ± 5%
PH pH meter Target ± 0.5
Buffer Specification Client Spec N/A
Purity A 260/280 Ratio UV Spec 1.70 ~ 2.30
Capping Efficiency LC-MS ≥ 90%
Size based purity Capillary Electrophoresis ≥ 75%
Impurity Total protein residue Nano Orange Assay ≤ 1%
Plasmid DNA Residue qPCR ≤ 0.1%
dsRNA Slot-blot ≤ 1%
Safety Endotoxin Semiquantitative < 10EU/mg
Endotoxin Quantitative < 10EU/mg
Bioburden Sdirect Inoculation No Growth after 48 hrs


Other Equipment by this Supplier

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.